High risk/high priority: Familial hypercholesterolemia - A paradigm for molecular medicine

Atherosclerosis Supplements

Volumn 2, Issue 4, 2002, Pages 27-32

  Schuster, Herbert ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Disease prevention; Familial hypercholesterolemia; Molecular characterization

Indexed keywords

ATORVASTATIN; CHOLESTEROL; DNA; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DNA DETERMINATION; DRUG EFFICACY; DRUG POTENCY; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY; GENETIC DISORDER; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MEASUREMENT; MEDICAL INFORMATION; MOLECULAR BIOLOGY; MORTALITY; PATIENT; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RELATIVE; RISK ASSESSMENT; CORONARY ARTERY ATHEROSCLEROSIS; GENETICS; HYPERLIPOPROTEINEMIA TYPE 2; REVIEW;

CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; RISK ASSESSMENT;

EID: 1242318565     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(01)00019-8     Document Type: Conference Paper

References (20)

1. Botto L.D., Khoury M.J. Commentary: facing the challenge of gene-environment interaction: the two-by-four table and beyond. Am. J. Epidemiol. 153:2001;1016-1020.
2. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., et al. The sequence of the human genome. Science. 291:2001;1304-1351.
3. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., et al. Initial sequencing and analysis of the human genome. Nature. 409:2001;860-921.
4. Haseltine W.A. Discovering genes for new medicines. Sci. Am. 276:1997;92-97.
5. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:1986;34-47.
6. Williams R.R., Hunt S.C., Schumacher M.C., Hegele R.A., Leppert M.F., Ludwig E.H., Hopkins P.N. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am. J. Cardiol. 72:1993;171-176.
7. Baron H., Fung S., Aydin A., Bahring S., Luft F.C., Schuster H. Oligonucleotide ligation assay (OLA) for the diagnosis of familial hypercholesterolemia. Nat. Biotechnol. 14:1996;1279-1282.
8. Brown M.S., Faust J.R., Goldstein J.L.I. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J. Biol. Chem. 253:1978;1121-1128.
9. LaRosa J.C., He J., Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. J. Am. Med. Assoc. 282:1999;2340-2346.
10. Stein E, Strutt KL, Miller E, Southworth H. ZD4522 is superior to atorvastatin in the treatment of patients with heterozygous familial hypercholesterolemia. J Am Coll Cardiol 2001;37 (Suppl A):292A. Abstract 1261-176.
11. Stein E, Strutt KL, Miller E, Southworth H. Rosuvastatin (20, 40 and 80 mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2001;Suppl 2:90-1. Abstract P176.
12. Havel R.J., Hunninghake D.B., Illingworth D.R., Lees R.S., Stein E.A., Tobert J.A., Bacon S.R., Bolognese J.A., Frost P.H., Lamkin G.E., et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia: a multi-center study. Ann. Intern. Med. 107:1987;609-615.
13. Stein E., Kreisberg R., Miller V., Mantell G., Washington L., Shapiro D.R. Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Arch. Intern. Med. 150:1990;341-345.
14. Heinonen T., Davila J., Davignon J., Black D.M. Two year treatment experience with high dose atorvastatin [abstract]. Atherosclerosis. 134:1997;125.
15. Marais A.D., Firth J.C., Bateman M.E., Byrnes P., Martens C., Mountney J. Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 17:1997;1527-1531.
16. Smilde T.J., van Wissen S., Wollersheim H., Trip M.D., Kastelein J.J.P., Stalenhoef A.F.H. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet. 357:2001;577-581.
17. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
18. Emery J., Hayflick S. The challenge of integrating genetic medicine into primary care. Br. Med. J. 322:2001;1027-1030.
19. Brown M.S., Goldstein J.L. Heart attacks: Gone with the century? (editorial). Science. 272:1996;629-632.
20. Goldstein J.L., Brown M.S. Molecular medicine. The cholesterol quartet. Science. 292:2001;1310-1312.